Avoid common mistakes on your manuscript.
Dear Reader,
Welcome to the final issue of Drugs in R&D for 2022.
I wish to reflect on this year’s achievements, and to thank all those who have contributed their time and effort to guarantee the quality of the content published in the journal.
In 2022, over 30 articles have been published. The high quality of content published in Drugs in R&D has been reflected in the most recent Impact Factor of 3.203 and CiteScore™ of 4.3.
I want to thank the authors of the articles published in Drugs in R&D over the course of 2022. The enthusiasm of all authors for their chosen fields and their willingness to contribute content to the journal are crucial for its continued success.
The quality of published articles is also testament to the diligence of the peer reviewers. I would like to acknowledge the following individuals who acted as reviewers for Drugs in R&D in the last 12 months:
Stacey Adam, USA
Bogdan Amuzescu, Romania
Alain Astier, France
Oyekoya Ayonrinde, Australia
Gabriela Barrientos, Argentina
Agatha Bastida, Spain
James Bell, UK
Agnieszka Bienert, Poland
Ato Bolek, Slovakia
Arun Butreddy, India
Cherie Butts, USA
Andrea Calvo, Italy
Anna Campello, Italy
Annalisa Campomori, Italy
Enrique Carrazana, USA
Tanju Çelik, Turkey
Jer-Ming Chang, Taiwan, Republic of China
Naveen Chella, India
Iwona Chlebicka, Poland
Magdalena Ciążyńska, Poland
Asim Bikas Das, India
Hans-Christoph Diener, Germany
Zoubir Djerada, France
Nancy A. Dreyer, USA
Noel O. Dybdal, USA
Josef Finsterer, Austria
Ruth Fritsch-Stork, Austria
Spyridon Gkalpakiotis, Czech Republic
Navin Goyal, USA
Stephen Greene, USA
Chelsey Grimbly, Canada
Paul Grootendorst, Canada
Tadeusz W. Hermann, Poland
Jan Hosek, Czech Republic
Dong-Liang Hu, Japan
Simon Hutchings, UK
Ei'Ichi Iizasa, Japan
Monica Jablonski, USA
Andre J. Jackson, USA
Anselm Jorda, Austria
Yasuyuki Kawamoto, Japan
Ryan Knox, USA
Andrew Lassman, USA
Bimal K. Malhotra, USA
Fiona Marra, UK
Catia Marzolini, Switzerland
Sarah A. McGraw, USA
Donovan McGrowder, Jamaica
Margarida Miranda, Portugal
Kenji Momo, Japan
Shigeo Muro, Japan
Natalia Navas, Spain
Deanna Nelson, USA
Przemysław Pączkowski, Poland
Jennifer Patterson, Spain
Frank Petavy, The Netherlands
Dima Qato, USA
Alessandro Rizzo, Italy
Rania Sarhan, Egypt
Sebastian Schloer, Germany
Ray Schuch, USA
Marie L.A. Schuttelaar, The Netherlands
Feng Shao, China
Cristiana Sieiro Santos, Spain
Nuno Silva, Portugal
Lorna Smith, UK
Adina Stan, Romania
Frantisek Stepanek, Czech Republic
Raju Subramanian, USA
Fatemeh Tabatabaie, Islamic Republic of Iran
Dhanusha Thambavita, Sri Lanka
Alberto Traverso, The Netherlands
Jakub Treml, Czech Republic
Malgorzata Trocha, Poland
Periklis Tsiros, Greece
Ruben van Eijk, The Netherlands
Maurits Vissers, The Netherlands
Bruno K. Vitturi, Brazil
Giau Van Vo, Viet Nam
Zhenlei Wang, China
Xiaoyu Yan, Hong Kong, China
Neville Yeomans, Australia
Mark Zimering, USA
I am also very grateful to the members of the journal’s Honorary Editorial Board, who have acted as peer reviewers and authors, and have provided guidance on journal content, policy and processes.
The editorial program for 2023 is well under way, and I am looking forward to bringing you many high-quality and authoritative articles in the field of pharmacology over the coming year.
I thank you for your continued support.
With best wishes,
Anton van Rensburg
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
About this article
Cite this article
Acknowledgement to Referees. Drugs R D 22, 255–256 (2022). https://doi.org/10.1007/s40268-022-00409-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40268-022-00409-z